Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth

Bibliography

• Sutcliffe R, Maguire D, Portmann B, Selection of patients with hepatocellular carcinoma for liver transplantation. Br J Surg 2006;93:11-8
   PubMed Web of Science ®Google Scholar
• Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005;23:8093-108
   PubMed Web of Science ®Google Scholar
• Liau KH, Ruo L, Shia J, Outcome of partial hepatectomy for large (>10 cm) hepatocellular carcinoma. Cancer 2005;104:1948-55
   PubMed Web of Science ®Google Scholar
• Tang ZY. Hepatocellular carcinoma surgery–review of the past and prospects for the 21st century. J Surg Oncol 2005;91:95-6
   PubMed Web of Science ®Google Scholar
• Rixe O, Ortuzar W, Alvarez M, Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem Pharmacol 1996;52:1855-65
   PubMed Web of Science ®Google Scholar
• Marchetti P, Galla DA, Russo FP, Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line. Anticancer Res 2004;24:219-26
   PubMed Web of Science ®Google Scholar
• Zhu AX, Blaszkowsky LS, Ryan DP, Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:1898-903
   PubMed Web of Science ®Google Scholar
• Li Y, Tian B, Yang J, Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol 2004;130:460-8
   PubMed Web of Science ®Google Scholar
• Nanjundan M, Nakayama Y, Cheng KW, Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 2007;67:3074-84
   PubMed Web of Science ®Google Scholar
• Lee JS, Chu IS, Heo J, Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667-76
   PubMed Web of Science ®Google Scholar
• Di Francesco AM, Ruggiero A, Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci 2002;59:1914-27
   PubMed Web of Science ®Google Scholar
• Ehrsson H, Wallin I, Yachnin J. Pharmacokinetics of oxaliplatin in humans. Med Oncol 2002;19:261-5
   PubMed Web of Science ®Google Scholar
• Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-56
   PubMed Web of Science ®Google Scholar
• Cory S, Vaux DL, Strasser A, Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res 1999;59:1685s-92s
   PubMed Web of Science ®Google Scholar
• Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64
   PubMed Web of Science ®Google Scholar
• Arango D, Wilson AJ, Shi Q, Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 2004;91:1931-46
   PubMed Web of Science ®Google Scholar
• Muto Y, Moriwaki H, Ninomiya M, Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996;334:1561-7
   PubMed Web of Science ®Google Scholar
• Holmes WF, Soprano DR, Soprano KJ. Early events in the induction of apoptosis in ovarian carcinoma cells by CD437: activation of the p38 MAP kinase signal pathway. Oncogene 2003;22(41):6377-86
   PubMed Web of Science ®Google Scholar
• Kirkin V, Joos S, Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004;1644:229-49
   PubMed Web of Science ®Google Scholar
• Manion MK, Hockenbery DM. Targeting BCL-2-related proteins in cancer therapy. Cancer Biol Ther 2003;2:105s-14s
   PubMed Web of Science ®Google Scholar
• Watanabe J, Kushihata F, Honda K, Bcl-xL overexpression in human hepatocellular carcinoma. Int J Oncol 2002;21:515-19
   PubMed Web of Science ®Google Scholar
• Hayward RL, MacPherson JS, Cummings J, Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: genetic evidence for specificity of the antisense effect. Mol Cancer Ther 2004;3:169-78
   PubMed Web of Science ®Google Scholar
• Bruix J, Hessheimer AJ, Forner A, New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 2006;25:3848-56
   PubMed Web of Science ®Google Scholar
• Ezhevsky SA, Dowdy SF. Protein transduction strategies for target and mechanism validation. In: Prendergast G, editor, Molecular cancer therapeutics. New Jersey: John Wiley; 2004
   Google Scholar
• Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-85
   PubMed Web of Science ®Google Scholar
• Yen Y, Lim DW, Chung V, Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial. Am J Clin Oncol 2008;31:317-22
   PubMed Web of Science ®Google Scholar
• Uhm JE, Park JO, Lee J, A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009;63:929-35
   PubMed Web of Science ®Google Scholar
• Asnacios A, Fartoux L, Romano O, Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008;112:2733-9
   PubMed Web of Science ®Google Scholar